IMVT
Immunovant, Inc.
$44.37
+0.05%
2026-08-21
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Key Fundamentals
Forward P/E
-16.73
EPS (TTM)
$-2.81
ROE
-80.1%
Profit Margin
0.0%
Debt/Equity
0.01
Price/Book
11.73
Beta
0.81
Market Cap
$8.64B
Avg Volume (10D)
1.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$45.42
60D Low
$30.26
Avg Volume
1.3M
Latest Close
$44.37
Get breakout alerts for IMVT
Sign up for Breakout Scanner to receive daily notifications when IMVT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Immunovant, Inc. (IMVT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IMVT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IMVT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.